PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, solidifying its position as a leading player in the industry. With the support of prominent investors such as Eight Roads, FIL Capital, and F-Prime, PlasmaGen has now raised over ₹600 crore to date.
The company operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical component in the production of life-saving therapies. Plasma fractionation is the process of separating plasma into its various components, such as albumin, immunoglobulins, and clotting factors, which are then used to create therapies for a range of diseases and conditions. The demand for these therapies is increasing globally, driven by an aging population and the growing prevalence of chronic diseases.
PlasmaGen’s state-of-the-art facility is designed to meet international standards, ensuring the production of high-quality plasma-derived therapies. The company’s products are used to treat a range of conditions, including bleeding disorders, immune deficiencies, and liver diseases. With its strong focus on quality and innovation, PlasmaGen has established itself as a trusted partner for hospitals, clinics, and pharmaceutical companies across India and beyond.
The funding round led by ViNS Bioproducts is a testament to the company’s growth potential and the confidence of investors in its business model. ViNS Bioproducts is a leading player in the biotechnology industry, with a strong track record of investing in innovative companies. The investment in PlasmaGen is expected to support the company’s expansion plans, including the enhancement of its manufacturing capabilities and the development of new products.
The Indian biotechnology sector has witnessed significant growth in recent years, driven by government initiatives, increasing investment, and a growing demand for innovative therapies. The sector is expected to continue its upward trajectory, with the Indian biotechnology market projected to reach $150 billion by 2025. PlasmaGen is well-positioned to capitalize on this growth, with its strong product portfolio, cutting-edge manufacturing facility, and experienced management team.
The company’s founders have a deep understanding of the biotechnology industry, with a strong background in research and development. They have built a talented team of scientists, engineers, and professionals who share their vision of creating innovative therapies that improve patient outcomes. With its strong leadership and commitment to excellence, PlasmaGen is poised to become a leading player in the global biotechnology industry.
In addition to its focus on product development and manufacturing, PlasmaGen is also committed to sustainability and social responsibility. The company has implemented various initiatives to reduce its environmental footprint, including the use of renewable energy sources and waste reduction programs. PlasmaGen also supports various community development programs, including education and healthcare initiatives, to promote the well-being of local communities.
The investment in PlasmaGen is a significant development for the Indian biotechnology sector, highlighting the growing interest of investors in the industry. The company’s success is expected to inspire other entrepreneurs and startups to pursue innovative ideas and create new opportunities in the sector. With its strong product portfolio, cutting-edge manufacturing facility, and commitment to sustainability and social responsibility, PlasmaGen is an exemplary model of a successful biotechnology company.
In conclusion, the funding round led by ViNS Bioproducts is a significant milestone for PlasmaGen Biosciences, valuing the company at over ₹1,500 crore. With its strong focus on innovation, quality, and sustainability, PlasmaGen is poised to become a leading player in the global biotechnology industry. The company’s success is a testament to the growing potential of the Indian biotechnology sector, which is expected to continue its upward trajectory in the coming years.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
